Zobrazeno 1 - 10
of 314
pro vyhledávání: '"Satoru, Motoyama"'
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Akiyuki Wakita, Satoru Motoyama, Yusuke Sato, Yushi Nagaki, Hiromu Fujita, Kohei Kemuriyama, Kenjiro Hayashi, Kazuhiro Imai, Hiroshi Nanjo, Yoshihiro Minamiya
Publikováno v:
Annals of Gastroenterological Surgery, Vol 7, Iss 6, Pp 904-912 (2023)
Abstract Aim Because the optimal treatment strategy for borderline resectable (cT3br) thoracic esophageal cancer patients remains unclear, it is of great interest whether preoperative neoadjuvant therapy for cT3br could achieve results comparable to
Externí odkaz:
https://doaj.org/article/42d6ee3685bb4878b6987e963cb66e86
Autor:
Yushi Nagaki, MD, PhD, Satoru Motoyama, MD, PhD, Yusuke Sato, MD, PhD, Akiyuki Wakita, MD, PhD, Hiromu Fujita, MD, PhD, Kohei Kemuriyama, MD, Ryohei Sasamori, MD, Shu Nozaki, MD, Kyoko Nomura, MD, PhD, Yoshihiro Minamiya, MD, PhD
Publikováno v:
Annals of Surgery Open, Vol 5, Iss 1, p e385 (2024)
Objective:. To test the hypothesis that neoadjuvant chemoradiotherapy (NACRT) is more effective against hot esophageal squamous cell carcinoma (ESCC) and that it may upregulate tumor immunogenicity. Background:. There have been several recent reports
Externí odkaz:
https://doaj.org/article/1614bd98c80e4e178dd88eb3ba46b0ef
Autor:
Yoshiro Nakahara, Taku Kouro, Satoru Motoyama, Masatomo Miura, Kazuma Fujita, Yuka Igarashi, Naoko Higashijima, Norikazu Matsuo, Hidetomo Himuro, Feifei Wei, Shun Horaguchi, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Haruhiro Saito, Koichi Azuma, Tetsuro Sasada
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2024)
Introduction: Clinical roles of plasma IL-6 levels have been reported in patients with various cancers, including non-small cell lung cancer (NSCLC), treated with immune checkpoint inhibitors (ICIs). However, the roles of other IL-6 signaling compone
Externí odkaz:
https://doaj.org/article/c99406045248454083cba711ad18ebf5
Autor:
Komei Kameyama, Kazuhiro Imai, Koichi Ishiyama, Shinogu Takashima, Shoji Kuriyama, Maiko Atari, Yoshiaki Ishii, Akihito Kobayashi, Shugo Takahashi, Mirai Kobayashi, Yuzu Harata, Yusuke Sato, Satoru Motoyama, Manabu Hashimoto, Kyoko Nomura, Yoshihiro Minamiya
Publikováno v:
Thoracic Cancer, Vol 13, Iss 5, Pp 708-715 (2022)
Abstract Background The aim of the present study was to use surgical and histological results to develop a simple noninvasive technique to improve nodal staging using preoperative PET/CT in patients with resectable lung cancer. Methods Preoperative P
Externí odkaz:
https://doaj.org/article/3b50da95323a4746a47b0f4008c2b038
Autor:
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Tumor regression grade (TRG) after neoadjuvant therapy is reportedly predictive of prognosis in esophageal cancer patients, as lack of a response to neoadjuvant therapy is associated with a poor prognosis. However, there is little
Externí odkaz:
https://doaj.org/article/58a1b64d044540da8428cd7ab6adf5cf
Autor:
Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu N. Asaka, Mayumi Niiyama, Masaki Imai, Akihiko Uda, Jasper Fuk-Woo Chan, Saori Takahashi, Jianbo An, Akari Saku, Ryota Nukiwa, Daichi Utsumi, Maki Kiso, Atsuhiro Yasuhara, Vincent Kwok-Man Poon, Chris Chung-Sing Chan, Yuji Fujino, Satoru Motoyama, Satoshi Nagata, Josef M. Penninger, Haruhiko Kamada, Kwok-Yung Yuen, Wataru Kamitani, Ken Maeda, Yoshihiro Kawaoka, Yasuhiro Yasutomi, Yumiko Imai, Keiji Kuba
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Endogenous ACE2 is a receptor for SARS-CoV-2 and a recombinant soluble ACE2 protein can inhibit SARS-CoV-2 infection acting as a decoy. Here the authors show that B38-CAP, an ACE2-like enzyme but not a decoy for the virus, is protective against SARS-
Externí odkaz:
https://doaj.org/article/37a0f877c7f0425f889b230ea8fdf522
Autor:
Kohei Kemuriyama, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Yushi Nagaki, Hiromu Fujita, Ryohei Sasamori, Kazuhiro Imai, Masaki Aokawa, Yoshihiro Minamiya
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background Video-assisted thoracoscopic surgery (VATS) is being used to treat esophageal submucosal tumors (SMTs) all over the world. However, this technique is difficult when the tumor is large and located on the left side wall of the esoph
Externí odkaz:
https://doaj.org/article/a59dd2392556439ea3d82a8a5602bde5
Autor:
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
Publikováno v:
World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background A pathological complete response (pCR) after neoadjuvant chemoradiotherapy (NACRT) ensures long-term survival in esophageal squamous cell carcinoma (ESCC) patients following esophagectomy, but pCR patients are a minority. The aim
Externí odkaz:
https://doaj.org/article/b3db0913aaa64709866e69f0b160e1e9
Autor:
Tsubasa Matsuo, Kazuhiro Imai, Hiroshi Nanjo, Shinogu Takashima, Yuko Hiroshima, Maiko Atari, Shoji Kuriyama, Yoshiaki Ishii, Yuki Wakamatsu, Yusuke Sato, Satoru Motoyama, Yuki Matsumura, Hiroyuki Suzuki, Kyoko Nomura, Yoshihiro Minamiya
Publikováno v:
Thoracic Cancer, Vol 12, Iss 8, Pp 1187-1194 (2021)
Abstract Background Immune checkpoint inhibitors (ICIs) are a promising advance in the treatment of patients with lung cancer. However, each ICI has been tested with an independently designed companion diagnostic assay that is based on a unique antib
Externí odkaz:
https://doaj.org/article/994feb1b4b914496bf9ef1acd194521f